December 18, 2025 — Leads & Copy — Pfizer Inc. (NYSE: PFE) will hold a conference call with investment analysts on Tuesday, February 3, 2026, at 10:00 a.m. EST to provide an update on the company’s Fourth Quarter and Full Year 2025 Performance Report.
Investors and the general public are invited to view and listen to the webcast of the call.
The Performance Report will be issued the morning of the call.
To access the webcast and view the report, visit www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at the same web address beginning today. Participants are advised to register in advance.
The conference call can also be accessed by dialing 800-456-4352 in the United States and Canada, or 785-424-1086 outside of the United States and Canada. The passcode is “10856”.
A transcript and webcast replay of the call will be available at www.pfizer.com/investors within 24 hours after the end of the live call and will be accessible for at least 90 days.
Pfizer applies science and global resources to bring therapies to people that extend and significantly improve their lives. The company strives to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.
Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures. The company collaborates with health care providers, governments and local communities to support and expand access to reliable, affordable health care.
Pfizer routinely posts information that may be important to investors on its website. To learn more, visit www.Pfizer.com and follow the company on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and Facebook at Facebook.com/Pfizer.
Disclosure Notice: The webcast may include forward-looking statements about anticipated operating and financial performance, including financial guidance and projections, reorganizations, business plans, strategy, goals and prospects; expectations for product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, launches, clinical trial results and other developing data, revenue contribution and projections, potential pricing and reimbursement, potential market dynamics, size and utilization rates, growth, performance, timing of exclusivity and potential benefits; strategic reviews; capital allocation objectives; dividends and share repurchases; plans for and prospects of acquisitions, dispositions and other business development activities; and ability to successfully capitalize on growth opportunities; expectations regarding manufacturing and product supply; ongoing efforts to respond to COVID-19; expectations regarding the impact of COVID-19 on business, operations and financial results; expectations regarding the impact of or changes to existing or new government regulations, laws or executive orders; and other statements about business, operations and financial results, that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. A description of these risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.
Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments.
Source: Pfizer Inc.
